The global phenylalanine market is predicted to reach US$ 743.25 million by 2026

 Phenylalanine is an amino acid that is naturally contained in mammalian breast milk. Humans and other animals that require phenylalanine or phenylalanine-containing proteins do not synthesize it de novo because it is an essential amino acid. Meat, chicken, fish, cottage cheese, lentils, peanuts, and sesame seeds are some of the foods that contain it. Tyrosine, epinephrine, norepinephrine, and dopamine are only a few of the chemicals produced by phenylalanine. When the body's supply of tyrosine is depleted, tyrosine is produced in the liver by hydroxylation of phenylalanine. Tyrosine is converted into adrenaline, norepinephrine, dopamine, and melanin, the tissue pigment, and is mostly used to make new proteins. Epinephrine and norepinephrine are crucial for stress management in the body, whereas dopamine is primarily responsible for pleasure in the brain.

Depression, attention deficit hyperactivity disorder (ADHD), Parkinson's illness, multiple sclerosis, vitiligo, acupuncture anesthesia, osteoarthritis, rheumatoid arthritis, weight reduction, and alcohol withdrawal symptoms are all treated with phenylalanine. Phenylalanine is a protein-producing amino acid that is utilized to control anxiety and depression levels. The global phenylalanine market is expected to be driven by an increase in the rate of depression among various age groups. Phenylketonuria is a condition that affects people who are born with a high level of phenylalanine in their blood (PKU). Phenylketonuria is a rare hereditary disorder characterized by an excess of the amino acid phenylalanine in the body. Seizures, hyperactivity, tremors, a musty odor in the breath, and sluggish growth are all common signs of PKU. As a result, the global market is constrained.

The global phenylalanine market is worth US$ 642.5 million in 2019 and is predicted to reach US$ 743.25 million by 2026, rising at a CAGR of 2.29 percent between 2020 and 2026.

The global phenylalanine market is divided into three types: D-Phenylalanine, DL-Phenylalanine, and L-Phenylalanine. Through the ingestion of dietary supplements, the L-form is used to build proteins in the body. In laboratories, the D-form is created. The DL-Form is a hybrid of the L and D shapes that are created in laboratories.

The global pharmaceutical industry is driving the global phenylalanine market. Phenylalanine is a neurotransmitter that stimulates brain cells in the central nervous system. It works well as a pain reliever. It's also utilized to boost the benefits of acupuncture and transcutaneous electrical nerve stimulation in the treatment of premenstrual syndrome and Parkinson's disease (TENS). Because of its analgesic and depressive qualities, DL-Phenylalanine is utilized as a nutritional supplement.

The global phenylalanine market can be divided into five regions: Asia Pacific, Europe, North America, the Middle East, and Africa, and Latin America. During the projected period, Asia Pacific is expected to account for a significant portion of the global market. People's anxiety and depression levels are rising in China and India, which are both densely populated countries. In the next years, this is projected to increase demand for long-term disease treatment and, as a result, demand for phenylalanine in the region. The demand for medications is being fueled by an increase in drug affordability, which is being fueled by the increasing number of low-cost generics being launched.

NOW Foods, Amazing Nutrition, LiftMode (Synaptent LLC), NutraMarks, Inc., and Shijiazhuang Jirong Pharmaceutical Co., Ltd. are among the leading competitors in the global phenylalanine market. To obtain market share, these companies engage in research and development, strategic alliances, and mergers and acquisitions.